General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Drug for Major Depressive Disorder ATLANTA, August 06, 2024--Alzamend Neuro Partners with Mass. General Hosp.

In this article we’ll explore the biggest losers of the ASX 100 and what Morningstar sees for them in the future. Tumbling 45 ...

Gold mining is global, but those who live and work around mines may not always see how global forces affect their communities ...

A major depressive episode may or may not accompany ... Mood stabilizer drugs are typically prescribed to prevent mood swings. Lithium is perhaps the best-known mood stabilizer, but newer drugs ...

Many kids and teens are looking forward to the holidays with great excitement, but others find it a difficult time of year ...

Antidepressants are prescription medications used to treat major depressive disorder (MDD ... To date, the most commonly used mood stabilizer is lithium. The following section will detail notable ...

Industry-wide lithium mine capacity reductions since the end of 2023 are estimated to lower lithium supplies by about 14% in ...

Growing demand for the lithium used in batteries for electric vehicles and energy storage has created a new frontier for mining in Nigeria. But it's led to exploitation of children who are often poor ...

Nov. 13, 2024 — An international team of scientists has identified a surprising factor that accelerates the degradation of lithium-ion batteries leading to a steady loss of charge. This ...

Relmada Therapeutics will halt two Phase III trials of a major depressive disorder drug after a futility assessment and ...

For the twenty-one million American adults experiencing major depressive disorder (MDD) annually, this FDA-cleared treatment ...

A study published in Environmental Science and Ecotechnology has revealed a strong connection between long-term air pollution ...